This can potentially be explained by a general downregulation of HRR pathways in ovarian cancer, owing to epigenetic silencing of the Fanconi’s anaemia pathway [73] or to mutations in HRR genes other than BRCA1 or BRCA2, e.g., BARD1, BRIP1, CHEK2, MRE11A, MSH6, NBN, PALB2, RAD50, RAD51C, or RAD51D [74,75]. This evidence concerns the gene BRCA1 and ovarian carcinoma.